National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology

National Institute on Drug Abuse Presents Data on Trevena’s TRV734 at the 57th Annual Meeting of the American College of Neuropsychopharmacology

CHESTERBROOK, PA — Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment options for patients in pain, today announced that TRV734 data were featured in a presentation at the 57th Annual Meeting of the American College of Neuropsychopharmacology as part of Trevena’s ongoing collaboration with the National Institute on Drug Abuse (NIDA).

The presentation, entitled “Modeling Opioid Maintenance Therapy in Rats: Effects of Chronic Buprenorphine and the Biased Mu-Opioid Receptor Agonist TRV130 on Relapse to Oxycodone Seeking,” was delivered by Yavin Shaham, Ph.D., Chief, Behavioral Neuroscience Research Branch, Intramural Research Program at NIDA. The presentation included data on Trevena compounds TRV130 and TRV734, and highlighted data showing that TRV734 reduced drug-seeking behavior in a rat model of relapse. These data suggest that TRV734 may be a novel, oral maintenance treatment for addiction to opioids or heroin.

READ:  Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

“Current therapies, such as methadone and buprenorphine, for patients with opioid abuse disorder have limited or no efficacy for some patients and are associated with substantial safety and tolerability concerns,” said Mark A. Demitrack, M.D., Sr. Vice President and Chief Medical Officer at Trevena. “We are encouraged by the data generated thus far and are pleased to continue our collaboration with NIDA to further investigate the potential use of TRV734 for this important unmet medical need.”

Preclinical studies performed by NIDA scientists suggest that biased mu opioid receptor ligands, like TRV734, may offer an alternative to current opioid maintenance therapies.

Source: Trevena, Inc., 955 Chesterbrook Blvd, Suite 200, Chesterbrook PA, 19087

Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.

Buy Us a Cup of Coffee